Safety and efficacy data from the MIV-711 phase II open label extension study presented at the OARSI world congress
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, has been presented as a poster during the Osteoarthritis Research Society International (OARSI) world congress. The poster title was Safety and Efficacy of Six Months´ Open Label Extension Post-RCT Using the Novel Cathepsin K Inhibitor MIV-711 in Patients with Osteoarthritis. Data from the six months’ open label extension study of MIV-711 in patients with osteoarthritis were presented. This study demonstrated that MIV-711 has acceptable safety and tolerability in